Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway.
Saved in:
| Title: | Endoglin inhibits prostate cancer motility via activation of the ALK2-Smad1 pathway. |
|---|---|
| Authors: | Craft CS; Division of Hematology/Oncology, Department of Medicine, Northwestern University Medical School, Northwestern University and the Robert H Lurie Cancer Center of Northwestern University, Chicago, IL, USA., Romero D, Vary CP, Bergan RC |
| Source: | Oncogene [Oncogene] 2007 Nov 08; Vol. 26 (51), pp. 7240-50. Date of Electronic Publication: 2007 May 14. |
| Publication Type: | Journal Article; Research Support, N.I.H., Extramural; Research Support, U.S. Gov't, Non-P.H.S. |
| Journal Info: | Publisher: Nature Publishing Group Country of Publication: England NLM ID: 8711562 Publication Model: Print-Electronic Cited Medium: Print ISSN: 0950-9232 (Print) Linking ISSN: 09509232 NLM ISO Abbreviation: Oncogene Subsets: MEDLINE |
| Database: | MEDLINE Ultimate |
Be the first to leave a comment!
